Get the Stockscreener App
8.82
25.46%
1.79
Vanda Pharmaceuticals Inc stock is traded at $8.82, with a volume of 23.74M.
It is up +25.46% in the last 24 hours and up +64.55% over the past month.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
See More
Previous Close:
$7.03
Open:
$8.53
24h Volume:
23.74M
Relative Volume:
17.93
Market Cap:
$521.23M
Revenue:
$192.64M
Net Income/Loss:
$2.51M
P/E Ratio:
168.32
EPS:
0.0524
Net Cash Flow:
$12.42M
1W Performance:
+27.64%
1M Performance:
+64.55%
6M Performance:
+86.86%
1Y Performance:
+84.13%
1-Day Range:
$8.50
$9.60
1-Week Range:
$6.87
$9.60
52-Week Range:
$3.8092
$9.60
Vanda Pharmaceuticals Inc Stock (VNDA) Company Profile
Name
Vanda Pharmaceuticals Inc
Sector
Industry
Phone
202-734-3400
Address
2200 PENNSYLVANIA AVE NW, WASHINGTON
Compare VNDA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VNDA
Vanda Pharmaceuticals Inc
|
8.82 | 415.45M | 192.64M | 2.51M | 12.42M | 0.0524 |
|
VRTX
Vertex Pharmaceuticals Inc
|
453.36 | 115.12B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.87 | 81.34B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.65 | 52.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
840.95 | 51.59B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.04 | 37.13B | 447.02M | -1.18B | -906.14M | -6.1812 |
Vanda Pharmaceuticals Inc Stock (VNDA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-05-25 | Initiated | B. Riley Securities | Buy |
| Oct-31-24 | Initiated | H.C. Wainwright | Buy |
| Jul-11-24 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-25-22 | Downgrade | Jefferies | Buy → Hold |
| May-12-21 | Initiated | BofA Securities | Buy |
| Jan-14-21 | Downgrade | Citigroup | Buy → Neutral |
| Oct-29-20 | Upgrade | Citigroup | Neutral → Buy |
| Jun-09-20 | Downgrade | Citigroup | Buy → Neutral |
| Mar-16-20 | Downgrade | Oppenheimer | Perform → Underperform |
| Mar-12-20 | Upgrade | Citigroup | Neutral → Buy |
| Nov-07-19 | Downgrade | Citigroup | Buy → Neutral |
| Aug-01-19 | Upgrade | Citigroup | Neutral → Buy |
| Jul-25-19 | Downgrade | Stifel | Buy → Hold |
| Dec-11-18 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-04-18 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Dec-04-18 | Reiterated | Jefferies | Buy |
| Nov-08-18 | Resumed | Jefferies | Buy |
| Sep-21-18 | Resumed | Oppenheimer | Outperform |
| May-23-18 | Initiated | Citigroup | Buy |
| Jan-19-18 | Initiated | Seaport Global Securities | Buy |
| Sep-14-17 | Reiterated | Piper Jaffray | Overweight |
| Jun-27-17 | Resumed | Piper Jaffray | Overweight |
| May-26-17 | Initiated | H.C. Wainwright | Buy |
| Apr-12-17 | Initiated | Oppenheimer | Outperform |
| Nov-09-16 | Initiated | Aegis Capital | Buy |
| Oct-06-16 | Resumed | Jefferies | Buy |
View All
Vanda Pharmaceuticals Inc Stock (VNDA) Latest News
Vanda stock jumps with FDA approval of motion sickness drug - BioWorld MedTech
Vanda Pharmaceuticals hits 3-year high after FDA approves Nereus | Tap to know more | Inshorts - Inshorts
D.C.-based Vanda gets FDA nod for motion-sickness treatment - The Business Journals
What's Going On With Vanda Pharmaceuticals Stock Wednesday? - Benzinga
Vanda Pharmaceuticals: Could Now Be A Good Time To Invest? - StocksToTrade
Vanda surges 28% after FDA approval - breakingthenews.net
B. Riley Securities Maintains Vanda Pharmaceuticals(VNDA.US) With Buy Rating, Raises Target Price to $14 - 富途牛牛
B. Riley Securities Raises Price Target for VNDA to $14.00 Maint - GuruFocus
Vanda Pharmaceuticals (NASDAQ:VNDA) Hits New 52-Week HighHere's What Happened - MarketBeat
Vanda Pharma's (VNDA) NEREUS Approval Boosts Growth Prospects - GuruFocus
Vanda Jumps 21% After FDA Approves Motion Sickness Therapy - GuruFocus
Vanda Pharmaceuticals Stock Jumps After FDA Approves Motion Sickness Drug - Barron's
Vanda Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:VNDA) - MarketBeat
Vanda Pharmaceuticals price target raised to $7.50 from $5 at Jefferies - TipRanks
Biggest Mover Wednesday: Vanda's FDA Win Sends the Stock Flying - GuruFocus
Biggest stock movers Wednesday: Vanda Pharmaceuticals and Cybin - MSN
Vanda Pharmaceuticals Stock Rockets: Time to Ride the Wave? - timothysykes.com
FDA approves Vanda Pharmaceuticals’ motion sickness drug Nereus - Pharmaceutical Technology
Vanda Pharmaceuticals (VNDA) Surges 21% on FDA Approval of Motion Sickness Drug - GuruFocus
Vanda Pharmaceuticals stock soars after FDA approval of motion sickness drug - Investing.com
VNDA: Jefferies Maintains Hold Rating, Raises Price Target to $7.50 | VNDA Stock News - GuruFocus
B. Riley Raises Price Target on Vanda Pharmaceuticals to $14 Form $11, Keeps Buy Rating - marketscreener.com
Vanda Pharmaceuticals surges as FDA approves motion sickness drug - Sharecast.com
Market news - investments.halifax.co.uk
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat
VNDA Obtains FDA Nod for Motion Sickness Drug, Stock Gains - Yahoo Finance
Vanda Pharmaceuticals (VNDA) Gains FDA Nod for Motion Sickness D - GuruFocus
Stock Movers: VANDA PHARMACEUTICALS , NIKE , SPX - Bloomberg.com
Vanda Wins FDA Approval for NEREUS Motion Sickness Drug - TipRanks
Jefferies raises Vanda Pharmaceuticals stock price target on motion sickness drug potential - Investing.com
Why Is VNDA Stock Surging Premarket? FDA Approves Motion Sickness Drug - Tokenist
Vanda Pharmaceuticals (VNDA) Surges on FDA Approval - GuruFocus
FDA Greenlights Vanda Pharmaceuticals' (VNDA) New Motion Sicknes - GuruFocus
Vanda Pharmaceuticals (VNDA) Shares Surge Following FDA Approval - GuruFocus
Vanda Pharma stock jumps premarket after FDA approves Nereus, first new motion-sickness vomiting drug in decades - ts2.tech
Trending tickers: latest investor updates on Nvidia, Caterpillar, Vanda Pharmaceuticals and Walker Crips - Yahoo Finance UK
Stock Market Today: S&P 500, Dow Jones Futures Down As Santa Rally Hopes Fade—Investors Await Initial Jobless Claims Report - Benzinga
US FDA approves Vanda Pharmaceuticals’ motion sickness drug - WTVB
Why Is Vanda Pharmaceuticals' (VNDA) Stock Trending Overnight? - Benzinga
US FDA approves Vanda Pharmaceuticals' motion sickness drug - ETPharma.com
US FDA approves Vanda Pharmaceuticals’ motion sickness drug By Reuters - Investing.com
US FDA Approves Vanda Pharmaceuticals' Motion Sickness Drug - U.S. News & World Report
Vanda Pharmaceuticals announces FDA approval of Nereus (tradipitant) - marketscreener.com
Vanda Pharmaceuticals Announces FDA Approval of NEREUS™ (tradipitant) for the Prevention of Vomiting Induced by Motion: A Historic Scientific Milestone in the Prevention of Motion Sickness - Nasdaq
3 Biotech Stocks With Major 2026 Catalysts - Yahoo Finance
The Christmas party is still ongoing in these stocks: Nvidia, Sidus Space, Coupang, Vanda Pharmaceuticals, ImmuCell - MSN
The Christmas Party Is Still Ongoing In These Stocks: Nvidia, Sidus Space, Coupang, Vanda Pharmaceuticals, ImmuCell - Asianet Newsable
Vanda’s FDA Moment: A High-Stakes Bet That Could Redefine The Stock - Stocktwits
Vanda Pharmaceuticals Stock Rallies on FDA Filing - Schaeffer's Investment Research
Vanda Pharmaceuticals (STU:VM4) EV-to-OCF : -1.36 (As of Dec. 21, 2025) - GuruFocus
Will Vanda Pharmaceuticals Inc. stock outperform tech sector in 2025Quarterly Portfolio Report & Accurate Entry/Exit Alerts - Улправда
Vanda Pharmaceuticals Inc Stock (VNDA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Vanda Pharmaceuticals Inc Stock (VNDA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Mitchell Stephen Ray | Director |
Jun 13 '25 |
Sale |
4.59 |
7,000 |
32,130 |
97,082 |
0.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):